title: Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
abstract: A better understanding of the angiogenic process has markedly expanded the use of antiangiogenic therapy in many solid tumors. It is known that there is a close relationship between cancer disease, vascular homeostasis, angiogenesis and coagulation cascade. In this setting, antiangiogenic therapy could interfere and potentially increase the risk of bleeding or thromboembolic events. Sunitinib is an orally available small molecule multikinase inhibitor recently approved for the treatment of unresectable or metastatic, well-differenciated pancreatic neuroendocrine tumors with disease progression in adults. Here we present the first case of a severe perirenal hematoma in a patient treated with sunitinib for metastatic pancreatic neuroendocrine tumor.
authors: Department of Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain. jonzuga@gmail.com
authors: Jon
authors: J
authors: Zugazagoitia
authors: Javier
authors: J
authors: Sastre
authors: Jerónimo
authors: J
authors: Barrera
authors: Beatriz
authors: B
authors: García
authors: Eduardo
authors: E
authors: Díaz-Rubio
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005260:Female; D006406:Hematoma / Q000150:complications / Q000000981:diagnostic imaging*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications / Q000000981:diagnostic imaging*; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011758:Pyrroles / Q000627:therapeutic use*; D011859:Radiography; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib